Cargando…

Advantages and applications of CAR-expressing natural killer cells

In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of inducing graft-versus-host disease (GvHD). In order to improve cytotoxicity against resistant cancer cells, auspicious efforts have been made with chimeric antigen receptor (CAR) expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glienke, Wolfgang, Esser, Ruth, Priesner, Christoph, Suerth, Julia D., Schambach, Axel, Wels, Winfried S., Grez, Manuel, Kloess, Stephan, Arseniev, Lubomir, Koehl, Ulrike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325659/ https://www.ncbi.nlm.nih.gov/pubmed/25729364 http://dx.doi.org/10.3389/fphar.2015.00021

Ejemplares similares

Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L(+) T Cells for Manufacturing of Gene Therapy Medicinal Products
por: Priesner, Christoph, et al.
Publicado: (2016)

Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering
por: Oberschmidt, Olaf, et al.
Publicado: (2019)

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells
por: Tischer, Sabine, et al.
Publicado: (2014)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
por: Oberschmidt, Olaf, et al.
Publicado: (2017)

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
por: Müller, Stephan, et al.
Publicado: (2020)

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18
por: Glienke, Wolfgang, et al.
Publicado: (2022)

NK cells engineered to express a GD(2)-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
por: Esser, Ruth, et al.
Publicado: (2012)

Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms
por: Priesner, Christoph, et al.
Publicado: (2016)

Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
por: Kloess, Stephan, et al.
Publicado: (2017)

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
por: Kloess, Stephan, et al.
Publicado: (2018)

Harnessing NK Cell Checkpoint-Modulating Immunotherapies
por: Chauhan, Sachin Kumar Singh, et al.
Publicado: (2020)

Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy
por: Suerth, Julia D., et al.
Publicado: (2014)

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Nowak, Juliette, et al.
Publicado: (2023)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
por: Merker, Michael, et al.
Publicado: (2017)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Production and Application of CAR T Cells: Current and Future Role of Europe
por: Vucinic, Vladan, et al.
Publicado: (2021)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies
por: Hofer, Erhard, et al.
Publicado: (2017)

Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids
por: Klöss, Stephan, et al.
Publicado: (2015)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Engineering CAR-T Cells for Improved Function Against Solid Tumors
por: Morgan, Michael A., et al.
Publicado: (2018)

Enhancement stimulants: perceived motivational and cognitive advantages
por: Ilieva, Irena P., et al.
Publicado: (2013)

Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections
por: Principi, Nicola, et al.
Publicado: (2019)

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing
por: Wagner, Dimitrios L., et al.
Publicado: (2022)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of Nanoparticles
por: Arms, Lauren, et al.
Publicado: (2018)

The Advantages of Connectivity Map Applied in Traditional Chinese Medicine
por: Jiang, Huimin, et al.
Publicado: (2021)

IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study
por: Brehm, Claudia, et al.
Publicado: (2011)

Advantages and Limitations of Current Imaging Techniques for Characterizing Liposome Morphology
por: Robson, Annie-Louise, et al.
Publicado: (2018)

Are natural killer cells superior CAR drivers?
por: Klingemann, Hans
Publicado: (2014)

Genome-Wide Analysis of Alpharetroviral Integration in Human Hematopoietic Stem/Progenitor Cells
por: Moiani, Arianna, et al.
Publicado: (2014)

Gene therapy on the move
por: Kaufmann, Kerstin B, et al.
Publicado: (2013)

Retroviral gene therapy in Germany with a view on previous experience and future perspectives
por: Morgan, Michael A., et al.
Publicado: (2021)

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
por: Giannattasio, Ariane, et al.
Publicado: (2015)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vrtb7eucfkccefr3afeavh03ig